Arkolith/Insider Trading/ACRV/Form 4

Gamelin Erick

Chief Development OfficerAcrivon Therapeutics, Inc. (ACRV) · full profile →Form 4 · filed May 16, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 14, 2025Tax withholding(F)403$1.14$45916K

Transaction Codes

F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000905148-25-001822) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML